Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma

Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer

“…Data of weekly chemotherapy are reported in a number of previous studies. 4,5 We encountered an overall response rate of 78.8%, which is superior to the 55.8% reported by Katsumata 8 but lower than the 92% reported by Safra et al 13 As in these studies, we have also used the WHO criteria 19 for clinical response evaluation. However, the median PFS of 12 months in our study was substantially lower than the 26 months reported by Safra et al 4 using weekly carboplatin and paclitaxel in the treatment of advanced ovarian carcinoma.…”

“…One would suspect that lower weekly doses of taxanes would mitigate toxicity. 4 However, Seidman et al 26 reported that neurotoxicity was a dose-limiting factor after weekly paclitaxel (80 mg/m 2 ) for the treatment of metastatic breast cancer. Thus, docetaxel seems to have a lower rate of disabling neurotoxicity than paclitaxel when given on a weekly schedule.…”

“…Promising activity and a favorable toxicity profile has been reported. 4,5 Higher total dose of paclitaxel (dose dense) can be achieved with weekly regimens and theoretically, may be superior to the standard 3-week schedule for first-line therapy. 6 Docetaxel is an alternative to paclitaxel in combination with a platinum agent in first-line chemotherapy but also for treatment of recurrent ovarian cancer.…”

A Pilot Study Evaluating a Novel Regimen Comprised of Carboplatin, Paclitaxel, and Bevacizumab for Advanced-Stage Ovarian Carcinoma

“…8 Standard dosing schedules (ie, every 3 weeks) for the treatment of advanced ovarian cancer have been associated with improved response rates and patient median PFS, although overall survival remains rather disappointing with relapse rates exceeding 70%. 2,3 Studies have since continued to evaluate whether weekly chemotherapy regimens significantly benefit cancer patients' prognosis and mitigate drug toxicity. 3,9Y11 Weekly chemotherapy regimens for the treatment of ovarian cancer have demonstrated promising activity with a favorable toxicity profile.…”

“…3,9Y11 Weekly chemotherapy regimens for the treatment of ovarian cancer have demonstrated promising activity with a favorable toxicity profile. 2,3 In particular, a higher total dose of paclitaxel can be achieved with weekly regimens and theoretically, may be superior to the standard 3-week schedule for first-line therapy. 9Y11 Bevacizumab has also been considered in weekly protocols because of the reported tolerability and efficacy; the regimen was administered on days 1 and 15 (10Y15 mg/kg) of a 28 day cycle.…”